Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152s) and conventional nucleosides in human immunodeficiency virus type 1-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 7, 1996, Pages 1657-1664

  Davey Jr , R T ^a   Chaitt, D G ^b   Reed, G F ^a   Freimuth, W W ^c   Herpin, B R ^a   Metcalf, J A ^a   Eastman, P S ^d   Falloon, J ^a   Kovacs, J A ^b   Polis, M A ^a   Walker, R E ^a   Masur, H ^b   Boyle, J ^a   Coleman, S ^a   Cox, S R ^c   Wathen, L ^c   Daenzer, C L ^c   Lane, H C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c PFIZER INC   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DELAVIRDINE; DIDANOSINE; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 8944232862     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.7.1657     Document Type: Article

References (22)

1. Balzarini, J., A. Karlsson, M. J. Perez-Perez, M. J. Camarasa, W. G. Tarpley, and E. De Clercq. 1993. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J. Virol. 67:5353-5359.
2. Cheeseman, S. H., D. Havlir, M. M. McLaughlin, T. C. Greenough, J. L. Sullivan, D. Hall, S. E. Hattox, S. A. Spector, D. S. Stein, M. Myers, and D. D. Richman. 1995. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 8:141-151.
3. Chong, K. T., P. J. Pagano, and R. R. Hinshaw. 1993. A novel BHAP, U-90152, is synergistic with 3′-azido-2′,3′-dideoxythymidine (AZT) and 2′,3′-dideoxycytidine (ddC) against HIV-1 replication in vitro, abstr. PO-A25-0606, p. 235. In Abstracts of the 4th International Conference on AIDS. University of Berlin, Berlin.
4. D'Aquila, R. T., V. A. Johnson, S. L. Welles, A. J. Japour, D. R. Kuritzkes, V. DeGruttola, P. S. Reichelderfer, R. W. Coombs, C. S. Crumpacker, J. O. Kahn, and D. D. Richman. 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann. Intern. Med. 122:401-408.
5. Davey, R. T., Jr., R. L. Dewar, G. F. Reed, M. H. Vasudevachari, M. A. Polis, J. A. Kovacs, J. Falloon, R. E. Walker, H. Masur, S. E. Haneiwich, D. G. O'Neill, M. R. Decker, J. A. Metcalf, M. A. Deloria, O. L. Laskin, N. Salzman, and H. C. Lane. 1993. Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661. Proc. Natl. Acad. Sci. USA 90:5608-5612.
6. Davey, R. T., Jr., and H. C. Lane. 1990. Laboratory methods in diagnosis and prognostic staging of HIV-1 infection. Rev. Infect. Dis. 12:912-930.
7. Dewar, R. L., H. C. Highbarger, M. D. Sarmiento, J. A. Todd, M. B. Vasudevachari, R. T. Davey, J. A. Kovacs, N. P. Salzman, H. C. Lane, and M. S. Urdea. 1994. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J. Infect. Dis. 170:1172-1179.
8. Dueweke, T. J., F. J. Kezdy, G. A. Waszak, M. R. Deibel, Jr., and W. G. Tarpley. 1992. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 267:27-30.
9. Dueweke, T. J., S. M. Poppe, D. L. Romero, S. S. Swaney, A. G. So, K. M. Downey, I. W. Althaus, F. Reusser, M. Busso, L. Resnick, D. L. Mayers, J. Lane, P. A. Aristoff, R. C. Thomas, and W. G. Tarpley. 1993. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 37:1127-1131.
10. Dueweke, T. J., T. Pushkarskaya, S. M. Poppe, S. S. Swaney, J. Q. Zhao, I. S. Y. Chen, M. Stevenson, and W. G. Tarpley. 1993. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 90:4713-4717.
11. Eastman, P. S., E. Boyer, L. Mole, J. Kohlberg, M. Urdea, and M. Holodniy. 1995. Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance. J. Clin. Microbiol. 33:2777-2780.
12. Fan, N., D. B. Evans, K. B. Rank, R. C. Thomas, W. G. Tarpley, and S. K. Sharma. 1995. Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. FEBS Lett. 359:233-238.
13. Havlir, D., S. H. Cheeseman, M. McLaughlin, R. Murphy, A. Erice, S. A. Spector, T. C. Greenough, J. L. Sullivan, D. Hall, M. Myers, M. Lamson, and D. D. Richman. 1995. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J. Infect. Dis. 171:537-545.
14. Holodniy, M., L. Mole, D. Margolis, J. Moss, H. Dong, E. Boyer, M. Urdea, J. Kolberg, and S. Eastman. 1995. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. J. Virol. 69:3510-3516.
15. Koot, M., I. P. Keet, A. H. Vos, R. E. de Goede, M. T. Roos, R. A. Coutinho, F. Miedema, P. T. Schellekens, and M. Tersmette. 1993. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann. Intern. Med. 118:681-688.
16. Pagano, P. J., and K. T. Chong. 1995. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha. J. Infect. Dis. 171:61-67.
17. Reichman, R. C., G. D. Morse, L. M. Demeter, L. Resnick, Y. Bassiakos, M. Fischl, M. Para, W. Powderly, J. Leedom, C. Greisberger, T. Nevin, K. Wood, P. M. Meehan, H. Geheb, S. Cox, D. Batts, J. Timpone, Jr., and ACTG 199 Study Team. 1995. Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. J. Infect. Dis. 171:297-304.
18. Richman, D. D. 1994. Resistance, drug failure, and disease progression. AIDS Res. Hum. Retroviruses 10:901-905.
19. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, C.-K. Shin, M. Myers, and J. Griffin. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666.
20. Romero, D. L., M. Busso, C. K. Tan, F. Reusser, J. R. Palmer, S. M. Poppe, P. A. Aristoff, K. M. Downey, A. G. So, L. Resnick, and W. G. Tarpley. 1991. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA 88:8806-8810.
21. Staszewski, S., F. E. Massari, A. Kober, R. Göhler, S. Durr, K. W. Anderson, C. L. Schneider, J. A. Waterbury, K. K. Bakshi, V. I. Taylor, C. S. Hildebrand, C. Kreisl, B. Hoffstedt, W. A. Schleif, H. von Briesen, H. Rübsamen-Waigmann, G. B. Calandra, J. L. Ryan, W. Stille, E. A. Emini, and V. W. Byrnes. 1995. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor. J. Infect. Dis. 171:1159-1165.
22. Volberding, P. 1995. The need for additional options in the treatment of human immunodeficiency virus infection. J. Infect. Dis. 171(Suppl. 2):S150-S154.